{"id":9870,"date":"2023-06-05T10:43:06","date_gmt":"2023-06-05T01:43:06","guid":{"rendered":"https:\/\/dev.rftcjapan.org\/pickup-article\/drug-cuts-risk-of-breast-cancer-recurrence-early-stage-patients-2\/"},"modified":"2023-06-05T10:43:06","modified_gmt":"2023-06-05T01:43:06","slug":"drug-cuts-risk-of-breast-cancer-recurrence-early-stage-patients","status":"publish","type":"post","link":"https:\/\/rftcjapan.org\/en\/pickup-article\/drug-cuts-risk-of-breast-cancer-recurrence-early-stage-patients\/","title":{"rendered":"Drug cuts risk of breast cancer recurrence for some early-stage patients, trial shows"},"content":{"rendered":"\n<h3 class=\"wp-block-heading\">When Drug cuts risk of breast cancer recurrence for some early-stage patients, trial shows<\/h3>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<p class=\"wp-block-paragraph\">By Jen Christensen, CNN<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">A drug used in people in the early stage of the most common kind of breast cancer \u2013 HR+\/HER2- breast cancer \u2013 significantly reduced the risk of the cancer returning after treatment, according to a new study.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The US Food and Drug Administration approved the Novartis drug ribociclib, marketed under the brand name <a href=\"https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/ribociclib-kisqali\" target=\"_blank\" rel=\"noopener\">Kisqali, in 2017<\/a> for people with cancer that has spread to other parts of the body, helping them live longer by slowing the disease\u2019s growth and spread. The results of a late-stage trial in people with early-stage cancer were presented Friday at the <a href=\"https:\/\/www.asco.org\/\" target=\"_blank\" rel=\"noopener\">American Society of Clinical Oncology<\/a> conference in Chicago. The drug is not yet indicated for this patient population.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u201cHaving seen that benefit, it made perfect sense to assess whether the same benefit can now be extended to a group of patients with breast cancer who are at a much earlier stage of their disease,\u201d Novartis\u2019 <a href=\"https:\/\/www.novartis.com\/about\/executive-committee\/shreeram-aradhye\" target=\"_blank\" rel=\"noopener\">Dr.<\/a> <a href=\"https:\/\/www.novartis.com\/about\/executive-committee\/shreeram-aradhye\" target=\"_blank\" rel=\"noopener\">Shreeram Aradhye<\/a>, president for global development and the company\u2019s chief medical officer, said at a news conference Friday. \u201cBreast cancer is often diagnosed at an earlier stage, but because it is picked up early, as in stage two or three, before it has spread, does not necessarily mean that those patients are not at risk of a potential recurrence.\u201d<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/edition.cnn.com\/2023\/06\/02\/health\/novartis-kisgali-reduces-breast-cancer-recurrence\/index.html\" target=\"_blank\" rel=\"noopener noreferrer\">Click here to read more<\/a><\/p>\n\n","protected":false},"excerpt":{"rendered":"<p>When Drug cuts risk of breast cancer recurrence for some early-stage patients, trial shows By Jen Christensen, CNN A drug used in people in the early stage of the most common kind of breast cancer \u2013 HR+\/HER2- breast cancer \u2013 significantly reduced the risk of the cancer returning after treatment, according to a new study. [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":10361,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[79],"tags":[282,80],"class_list":["post-9870","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pickup-article","tag-breast-cancer-awareness-en","tag-breast-cancer-ja"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Drug cuts risk of breast cancer recurrence for some early-stage patients, trial shows - RFTC Japan<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/rftcjapan.org\/en\/pickup-article\/drug-cuts-risk-of-breast-cancer-recurrence-early-stage-patients\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Drug cuts risk of breast cancer recurrence for some early-stage patients, trial shows - RFTC Japan\" \/>\n<meta property=\"og:description\" content=\"When Drug cuts risk of breast cancer recurrence for some early-stage patients, trial shows By Jen Christensen, CNN A drug used in people in the early stage of the most common kind of breast cancer \u2013 HR+\/HER2- breast cancer \u2013 significantly reduced the risk of the cancer returning after treatment, according to a new study. [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/rftcjapan.org\/en\/pickup-article\/drug-cuts-risk-of-breast-cancer-recurrence-early-stage-patients\/\" \/>\n<meta property=\"og:site_name\" content=\"RFTC Japan\" \/>\n<meta property=\"article:published_time\" content=\"2023-06-05T01:43:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/rftcjapan.org\/wpdata\/wp-content\/uploads\/2026\/06\/Screen-Shot-2023-06-05-at-10.34.24.png\" \/>\n\t<meta property=\"og:image:width\" content=\"992\" \/>\n\t<meta property=\"og:image:height\" content=\"553\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"michael\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"michael\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/rftcjapan.org\\\/en\\\/pickup-article\\\/drug-cuts-risk-of-breast-cancer-recurrence-early-stage-patients\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/rftcjapan.org\\\/en\\\/pickup-article\\\/drug-cuts-risk-of-breast-cancer-recurrence-early-stage-patients\\\/\"},\"author\":{\"name\":\"michael\",\"@id\":\"https:\\\/\\\/rftcjapan.org\\\/#\\\/schema\\\/person\\\/5f9c8ca2f816ff93dec0cfdff2303f89\"},\"headline\":\"Drug cuts risk of breast cancer recurrence for some early-stage patients, trial shows\",\"datePublished\":\"2023-06-05T01:43:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/rftcjapan.org\\\/en\\\/pickup-article\\\/drug-cuts-risk-of-breast-cancer-recurrence-early-stage-patients\\\/\"},\"wordCount\":248,\"image\":{\"@id\":\"https:\\\/\\\/rftcjapan.org\\\/en\\\/pickup-article\\\/drug-cuts-risk-of-breast-cancer-recurrence-early-stage-patients\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/rftcjapan.org\\\/wpdata\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/Screen-Shot-2023-06-05-at-10.34.24.png\",\"keywords\":[\"breast-cancer-awareness-en\",\"breast-cancer-ja\"],\"articleSection\":[\"Pickup\u8a18\u4e8b\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/rftcjapan.org\\\/en\\\/pickup-article\\\/drug-cuts-risk-of-breast-cancer-recurrence-early-stage-patients\\\/\",\"url\":\"https:\\\/\\\/rftcjapan.org\\\/en\\\/pickup-article\\\/drug-cuts-risk-of-breast-cancer-recurrence-early-stage-patients\\\/\",\"name\":\"Drug cuts risk of breast cancer recurrence for some early-stage patients, trial shows - RFTC Japan\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/rftcjapan.org\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/rftcjapan.org\\\/en\\\/pickup-article\\\/drug-cuts-risk-of-breast-cancer-recurrence-early-stage-patients\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/rftcjapan.org\\\/en\\\/pickup-article\\\/drug-cuts-risk-of-breast-cancer-recurrence-early-stage-patients\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/rftcjapan.org\\\/wpdata\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/Screen-Shot-2023-06-05-at-10.34.24.png\",\"datePublished\":\"2023-06-05T01:43:06+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/rftcjapan.org\\\/#\\\/schema\\\/person\\\/5f9c8ca2f816ff93dec0cfdff2303f89\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/rftcjapan.org\\\/en\\\/pickup-article\\\/drug-cuts-risk-of-breast-cancer-recurrence-early-stage-patients\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/rftcjapan.org\\\/en\\\/pickup-article\\\/drug-cuts-risk-of-breast-cancer-recurrence-early-stage-patients\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/rftcjapan.org\\\/en\\\/pickup-article\\\/drug-cuts-risk-of-breast-cancer-recurrence-early-stage-patients\\\/#primaryimage\",\"url\":\"https:\\\/\\\/rftcjapan.org\\\/wpdata\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/Screen-Shot-2023-06-05-at-10.34.24.png\",\"contentUrl\":\"https:\\\/\\\/rftcjapan.org\\\/wpdata\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/Screen-Shot-2023-06-05-at-10.34.24.png\",\"width\":992,\"height\":553},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/rftcjapan.org\\\/en\\\/pickup-article\\\/drug-cuts-risk-of-breast-cancer-recurrence-early-stage-patients\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/rftcjapan.org\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Drug cuts risk of breast cancer recurrence for some early-stage patients, trial shows\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/rftcjapan.org\\\/#website\",\"url\":\"https:\\\/\\\/rftcjapan.org\\\/\",\"name\":\"RFTC Japan\",\"description\":\"Japan&#039;s Leading Breast Cancer Foundation\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/rftcjapan.org\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/rftcjapan.org\\\/#\\\/schema\\\/person\\\/5f9c8ca2f816ff93dec0cfdff2303f89\",\"name\":\"michael\",\"sameAs\":[\"https:\\\/\\\/rftcjapan.org\\\/wpdata\"],\"url\":\"https:\\\/\\\/rftcjapan.org\\\/en\\\/author\\\/michael\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Drug cuts risk of breast cancer recurrence for some early-stage patients, trial shows - RFTC Japan","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/rftcjapan.org\/en\/pickup-article\/drug-cuts-risk-of-breast-cancer-recurrence-early-stage-patients\/","og_locale":"en_US","og_type":"article","og_title":"Drug cuts risk of breast cancer recurrence for some early-stage patients, trial shows - RFTC Japan","og_description":"When Drug cuts risk of breast cancer recurrence for some early-stage patients, trial shows By Jen Christensen, CNN A drug used in people in the early stage of the most common kind of breast cancer \u2013 HR+\/HER2- breast cancer \u2013 significantly reduced the risk of the cancer returning after treatment, according to a new study. [&hellip;]","og_url":"https:\/\/rftcjapan.org\/en\/pickup-article\/drug-cuts-risk-of-breast-cancer-recurrence-early-stage-patients\/","og_site_name":"RFTC Japan","article_published_time":"2023-06-05T01:43:06+00:00","og_image":[{"width":992,"height":553,"url":"https:\/\/rftcjapan.org\/wpdata\/wp-content\/uploads\/2026\/06\/Screen-Shot-2023-06-05-at-10.34.24.png","type":"image\/png"}],"author":"michael","twitter_card":"summary_large_image","twitter_misc":{"Written by":"michael","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/rftcjapan.org\/en\/pickup-article\/drug-cuts-risk-of-breast-cancer-recurrence-early-stage-patients\/#article","isPartOf":{"@id":"https:\/\/rftcjapan.org\/en\/pickup-article\/drug-cuts-risk-of-breast-cancer-recurrence-early-stage-patients\/"},"author":{"name":"michael","@id":"https:\/\/rftcjapan.org\/#\/schema\/person\/5f9c8ca2f816ff93dec0cfdff2303f89"},"headline":"Drug cuts risk of breast cancer recurrence for some early-stage patients, trial shows","datePublished":"2023-06-05T01:43:06+00:00","mainEntityOfPage":{"@id":"https:\/\/rftcjapan.org\/en\/pickup-article\/drug-cuts-risk-of-breast-cancer-recurrence-early-stage-patients\/"},"wordCount":248,"image":{"@id":"https:\/\/rftcjapan.org\/en\/pickup-article\/drug-cuts-risk-of-breast-cancer-recurrence-early-stage-patients\/#primaryimage"},"thumbnailUrl":"https:\/\/rftcjapan.org\/wpdata\/wp-content\/uploads\/2026\/06\/Screen-Shot-2023-06-05-at-10.34.24.png","keywords":["breast-cancer-awareness-en","breast-cancer-ja"],"articleSection":["Pickup\u8a18\u4e8b"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/rftcjapan.org\/en\/pickup-article\/drug-cuts-risk-of-breast-cancer-recurrence-early-stage-patients\/","url":"https:\/\/rftcjapan.org\/en\/pickup-article\/drug-cuts-risk-of-breast-cancer-recurrence-early-stage-patients\/","name":"Drug cuts risk of breast cancer recurrence for some early-stage patients, trial shows - RFTC Japan","isPartOf":{"@id":"https:\/\/rftcjapan.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/rftcjapan.org\/en\/pickup-article\/drug-cuts-risk-of-breast-cancer-recurrence-early-stage-patients\/#primaryimage"},"image":{"@id":"https:\/\/rftcjapan.org\/en\/pickup-article\/drug-cuts-risk-of-breast-cancer-recurrence-early-stage-patients\/#primaryimage"},"thumbnailUrl":"https:\/\/rftcjapan.org\/wpdata\/wp-content\/uploads\/2026\/06\/Screen-Shot-2023-06-05-at-10.34.24.png","datePublished":"2023-06-05T01:43:06+00:00","author":{"@id":"https:\/\/rftcjapan.org\/#\/schema\/person\/5f9c8ca2f816ff93dec0cfdff2303f89"},"breadcrumb":{"@id":"https:\/\/rftcjapan.org\/en\/pickup-article\/drug-cuts-risk-of-breast-cancer-recurrence-early-stage-patients\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/rftcjapan.org\/en\/pickup-article\/drug-cuts-risk-of-breast-cancer-recurrence-early-stage-patients\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/rftcjapan.org\/en\/pickup-article\/drug-cuts-risk-of-breast-cancer-recurrence-early-stage-patients\/#primaryimage","url":"https:\/\/rftcjapan.org\/wpdata\/wp-content\/uploads\/2026\/06\/Screen-Shot-2023-06-05-at-10.34.24.png","contentUrl":"https:\/\/rftcjapan.org\/wpdata\/wp-content\/uploads\/2026\/06\/Screen-Shot-2023-06-05-at-10.34.24.png","width":992,"height":553},{"@type":"BreadcrumbList","@id":"https:\/\/rftcjapan.org\/en\/pickup-article\/drug-cuts-risk-of-breast-cancer-recurrence-early-stage-patients\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/rftcjapan.org\/"},{"@type":"ListItem","position":2,"name":"Drug cuts risk of breast cancer recurrence for some early-stage patients, trial shows"}]},{"@type":"WebSite","@id":"https:\/\/rftcjapan.org\/#website","url":"https:\/\/rftcjapan.org\/","name":"RFTC Japan","description":"Japan&#039;s Leading Breast Cancer Foundation","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/rftcjapan.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/rftcjapan.org\/#\/schema\/person\/5f9c8ca2f816ff93dec0cfdff2303f89","name":"michael","sameAs":["https:\/\/rftcjapan.org\/wpdata"],"url":"https:\/\/rftcjapan.org\/en\/author\/michael\/"}]}},"_links":{"self":[{"href":"https:\/\/rftcjapan.org\/en\/wp-json\/wp\/v2\/posts\/9870","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/rftcjapan.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/rftcjapan.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/rftcjapan.org\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/rftcjapan.org\/en\/wp-json\/wp\/v2\/comments?post=9870"}],"version-history":[{"count":0,"href":"https:\/\/rftcjapan.org\/en\/wp-json\/wp\/v2\/posts\/9870\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/rftcjapan.org\/en\/wp-json\/wp\/v2\/media\/10361"}],"wp:attachment":[{"href":"https:\/\/rftcjapan.org\/en\/wp-json\/wp\/v2\/media?parent=9870"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/rftcjapan.org\/en\/wp-json\/wp\/v2\/categories?post=9870"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/rftcjapan.org\/en\/wp-json\/wp\/v2\/tags?post=9870"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}